Mechanism of Action and Clinical Potential of Fingolimod for the Treatment of Stroke
Fingolimod (FTY720) is an orally bio-available immunomodulatory drug currently approved by the FDA for the treatment of multiple sclerosis. Currently, there is a significant interest in the potential benefits of FTY720 on stroke outcomes. FTY720 and the sphingolipid signaling pathway it modulates ha...
Main Authors: | Wentao Li, Haoliang Xu, Fernando Daniel Testai |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2016-08-01
|
Series: | Frontiers in Neurology |
Subjects: | |
Online Access: | http://journal.frontiersin.org/Journal/10.3389/fneur.2016.00139/full |
Similar Items
-
Preclinical Evaluation of Fingolimod in Rodent Models of Stroke With Age or Atherosclerosis as Comorbidities
by: Andrea C. Diaz Diaz, et al.
Published: (2022-07-01) -
Sphingosine-1-Phosphate Signaling in Ischemic Stroke: From Bench to Bedside and Beyond
by: Shuo-Qi Zhang, et al.
Published: (2021-11-01) -
The emerging role of FTY720 as a sphingosine 1‐phosphate analog for the treatment of ischemic stroke: The cellular and molecular mechanisms
by: Maryam Naseh, et al.
Published: (2021-06-01) -
Serum Sphingosine 1-Phosphate (S1P): A Novel Diagnostic Biomarker in Early Acute Ischemic Stroke
by: Jia Liu, et al.
Published: (2020-09-01) -
Mechanisms of Preconditioning Exercise-Induced Neurovascular Protection in Stroke
by: Sherif Hafez, et al.
Published: (2021-09-01)